SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 16   

Articles published

SCLN 4.37 0.00 (0.00%)
price chart
SciClone Pharmaceuticals Stock Downgraded (SCLN)
SCICLONE PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
SciClone Reserves $2 Million For FCPA Settlement
SciClone Pharmaceuticals Inc. said it has reserved $2 million for penalties tied to an ongoing foreign bribery probe. The pharmaceutical firm said in a securities filing that a settlement of that size, minuscule for a Foreign Corrupt Practices Act ...
SciClone to Present at Needham Healthcare Conference on April 8, 2014
FOSTER CITY, CA--(Marketwired - Apr 1, 2014) - SciClone Pharmaceuticals, Inc. ( NASDAQ : SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 13th Needham Healthcare ...
Related articles »  
The Morning Risk Report: US Sanctions Target Russian 'Cronies,' Not Companies
SciClone prepares for settlement. SciClone Pharmaceuticals Inc. said it has reserved $2 million for penalties tied to an ongoing foreign bribery probe.
Related articles »  
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 ...
Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ:SCLN) in China for SGX942 in the treatment of oral mucositis.
Related articles »  
Sciclone Pharmaceuticals Inc gives FY 2014 revenue guidance
Sciclone Pharmaceuticals Inc Lowers FY 2013 Guidance